Biologic outcome in 4 patient age groups during treatment with HU
. | Group age at inclusion, y (n) . | . | . | . | |||
|---|---|---|---|---|---|---|---|
. | Younger than 2 (10) . | 2 to 5 (28) . | 6 to 9 (25) . | 10 to 19 (26) . | |||
| At inclusion | |||||||
| Hemoglobin level, g/dL | 8.2 (6.5-12) | 8.1 (6.3-10) | 7.9 (6.4-10) | 8.7 (7.0-10) | |||
| HbF leve, g/dL | 0.66 (0.52-2.4) | 0.59 (0.15-2.2) | 0.46 (0.03-2.8) | 0.41 (0.15-2.5) | |||
| MCV, fL | 79 (73-93) | 82 (68-113) | 85 (67-95) | 88 (70-101) | |||
| ANC, × 109/L | 6.5 (2.4-8.4) | 5.6 (2.4-12) | 5.7 (2.7-17) | 5.7 (2.8-11) | |||
| Second-year HU | |||||||
| Hemoglobin level, g/dL | 7.6 (2.3-10) | 8.9† (6.2-12) | 8.6† (6.5-12) | 8.9 (7.1-12) | |||
| HbF leve, g/dL | 1.6* (0.35-2.4) | 1.5† (0.24-4.3) | 1.3* (0.12-4.5) | 1.3* (0.15-3.8) | |||
| MCV, fL | 94* (74-109) | 91* (81-102) | 92* (80-117) | 96* (70-110) | |||
| ANC, × 109/L | 4.2 (1.4-7.3) | 5.0 (2.5-10) | 4.1* (1.3-12) | 3.9* (1.3-9.5) | |||
. | Group age at inclusion, y (n) . | . | . | . | |||
|---|---|---|---|---|---|---|---|
. | Younger than 2 (10) . | 2 to 5 (28) . | 6 to 9 (25) . | 10 to 19 (26) . | |||
| At inclusion | |||||||
| Hemoglobin level, g/dL | 8.2 (6.5-12) | 8.1 (6.3-10) | 7.9 (6.4-10) | 8.7 (7.0-10) | |||
| HbF leve, g/dL | 0.66 (0.52-2.4) | 0.59 (0.15-2.2) | 0.46 (0.03-2.8) | 0.41 (0.15-2.5) | |||
| MCV, fL | 79 (73-93) | 82 (68-113) | 85 (67-95) | 88 (70-101) | |||
| ANC, × 109/L | 6.5 (2.4-8.4) | 5.6 (2.4-12) | 5.7 (2.7-17) | 5.7 (2.8-11) | |||
| Second-year HU | |||||||
| Hemoglobin level, g/dL | 7.6 (2.3-10) | 8.9† (6.2-12) | 8.6† (6.5-12) | 8.9 (7.1-12) | |||
| HbF leve, g/dL | 1.6* (0.35-2.4) | 1.5† (0.24-4.3) | 1.3* (0.12-4.5) | 1.3* (0.15-3.8) | |||
| MCV, fL | 94* (74-109) | 91* (81-102) | 92* (80-117) | 96* (70-110) | |||
| ANC, × 109/L | 4.2 (1.4-7.3) | 5.0 (2.5-10) | 4.1* (1.3-12) | 3.9* (1.3-9.5) | |||